TOP > 外国特許検索 > THERAPEUTIC AGENT ASSOCIATED WITH SUPPRESSION OF PROLIFERATION AND METASTASIS OF TUMOR, WHICH COMPRISES EXOSOMES RELEASED FROM CYTOTOXIC T CELLS AND TARGETS CANCER STROMAL/MESENCHYMAL CELLS

THERAPEUTIC AGENT ASSOCIATED WITH SUPPRESSION OF PROLIFERATION AND METASTASIS OF TUMOR, WHICH COMPRISES EXOSOMES RELEASED FROM CYTOTOXIC T CELLS AND TARGETS CANCER STROMAL/MESENCHYMAL CELLS

外国特許コード F160008902
整理番号 (S2015-0848-N0)
掲載日 2016年11月11日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP058721
国際公開番号 WO 2016152786
国際出願日 平成28年3月18日(2016.3.18)
国際公開日 平成28年9月29日(2016.9.29)
優先権データ
  • 特願2015-058467 (2015.3.20) JP
発明の名称 (英語) THERAPEUTIC AGENT ASSOCIATED WITH SUPPRESSION OF PROLIFERATION AND METASTASIS OF TUMOR, WHICH COMPRISES EXOSOMES RELEASED FROM CYTOTOXIC T CELLS AND TARGETS CANCER STROMAL/MESENCHYMAL CELLS
発明の概要(英語) [Problem] To provide a therapeutic agent which can suppress cell proliferation and metastasis of a tumor or the like. [Solution] Provided is a therapeutic agent for cell-proliferative diseases, which comprises extracellular vesicles (exosomes) released from cytotoxic T cells. The therapeutic agent targets cancer stromal/mesenchymal cells and can suppress the proliferation and metastasis of a tumor including cancer.
特許請求の範囲(英語) [claim1]
1. The cell outside vesicle which is discharged from the cell injury characteristic T cell ([ekisosomu]) the remedy for the cell vegetating disease which is included.
[claim2]
2. As for the aforementioned cell injury characteristic T cell, person CD4 (+), CD8 (+), CD9 (+), CD63 (+,) TCR (+) the cell outside vesicle which among the T cells at least from 1 or 2 or more is discharged ([ekisosomu]) the remedy for cell vegetating disease of the claim 1 statement which is included.
[claim3]
3. As for the aforementioned cell injury characteristic T cell, CD8 (+) the cell outside vesicle which is discharged from the T cell ([ekisosomu]) the cell outside vesicle which is ([ekisosomu]) the remedy for cell vegetating disease of the claim 2 statement which is included.
[claim4]
4. The aforementioned cell outside vesicle ([ekisosomu]), the claim the remedy for cell vegetating disease of 2 which features that miRNA which is effective to cell multiplication control is included or 3 statements.
[claim5]
5. The remedy for cell vegetating disease of the claim 4 statement which features that miRNA which is effective to the aforementioned cell multiplication control is included.
[claim6]
6. The remedy for the aforementioned cell vegetating disease, the bactericide, the mucous membrane removal medicine, the isotonic conversion medicine, the pH modifier and the stabilization medicine, the thickener, 1 where it is selected from midst of the antiseptic, the adhesive or the immunity strengthening medicine or the remedy for cell vegetating disease of the claim 2 statement which furthermore contains plural.
[claim7]
7. As for the aforementioned remedy the mesenchyme type cell which is while tumor organizing and while tumor organizing, in the claim 2 which features the vein or that it is prescribed under the skin the remedy for cell vegetating disease of statement.
[claim8]
8. [ekisosomu] which is discharged from the cell injury characteristic T cell is collected, miRNA which is effective to cell multiplication control from that [ekisosomu] extraction method for the cell vegetating disease remedy miRNA which specifies.
[claim9]
9. In claim 8 the remedy for the cell vegetating disease which features that miRNA which is effective to the cell multiplication control which is obtained by the method of statement is included.
[claim10]
10. As miRNA which specifies by the method of statement the culture human mesenchyme type trunk cell (MSC) adding miRNA which has the same base arrangement in claim, 8 identification method of the MSC injury characteristic miRNA which appraises the MSC injury characteristic of miRNA by culturing, you inspect the obstacle activity for MSC.
[claim11]
11. In claim 10 the remedy for the cell vegetating disease which includes the MSC injury characteristic miRNA which is identified by the method of statement.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • MIE UNIVERSITY
  • KYOTO UNIVERSITY
  • 発明者(英語)
  • SHIKU HIROSHI
  • SEO NAOHIRO
  • AKIYOSHI KAZUNARI
  • HARADA NAOZUMI
  • MOMOSE FUMIYASU
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
さらに詳しい情報をご要望の方は、下記「問合せ先」までお問い合わせください。未公開情報等の交換をおこなう場合は秘密保持契約を締結しての面談等にて対応しております。

PAGE TOP

close
close
close
close
close
close